Jefferies Stays on Sidelines with Myriad (MYGN) after DNA Ruling
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
Go back to Jefferies Stays on Sidelines with Myriad (MYGN) after DNA Ruling
June 14, 2013 6:46 AM EDT
BofA/Merrill Lynch downgraded Myriad Genetics (NASDAQ: MYGN) from Buy to Neutral.
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.
Shares of Myriad Genetics closed at $32.01 yesterday, with a 52 week range of $22.02-$38.27.... More
June 14, 2013 6:45 AM EDT
RBC Capital downgraded Myriad Genetics (NASDAQ: MYGN) from Outperform to Sector Perform with a price target of $32.00 (unchanged).
For an analyst ratings summary and ratings history on Myriad Genetics click here. For... More
June 14, 2013 6:44 AM EDT
JMP Securities upgraded Myriad Genetics (NASDAQ: MYGN) from Market Perform to Market Outperform with a price target of $48.00.
For an analyst ratings summary and ratings history on Myriad Genetics click here. For... More
June 13, 2013 2:44 PM EDT
Leerink Swann downgraded Myriad Genetics (NASDAQ: MYGN) from Outperform to Market Perform with a price target of $39.00. Analyst Dan Leonard thinks investor focus will now turn to competition and the stock has no place to go but down.
"Following the Supreme Court's... More
June 13, 2013 1:50 PM EDT
Piper Jaffray today maintained an Overweight rating on Myriad Genetics (NASDAQ: MYGN) and raised its price target to a Street-high $49.00 (from $39.00).
For an analyst ratings summary and ratings history on Myriad Genetics click... More
June 13, 2013 10:55 AM EDT
Myriad Genetics (Nasdaq: MYGN) posted the following response to the U.S. Supreme Court ruling made earlier on its Facebook page:
"The Supreme Court has... More
June 13, 2013 10:26 AM EDT
Myriad Genetics, Inc. (NASDAQ: MYGN) trading paused due to limit up, limit down.... More
June 13, 2013 10:24 AM EDT
(Updated - June 13, 2013 10:33 AM EDT)
Gene patent limited by high court in mixed ruling for Myriad Genetics, Inc. (NASDAQ: MYGN), according to Bloomberg headlines.
For the U.S. Supreme Court document (pdf format), click here.
Myriad is up 9 percent on the session.... More
